Uganda Ends Ebola Outbreak as Congo Tests Vaccine Against Same Strain
Uganda declared its Bundibugyo Ebola outbreak over on August 27, 2026, after completing the internationally recognized 42-day monitoring period, while the Democratic Republic of the Congo began vaccinating frontline workers and contacts as its larger outbreak continued to spread across six provinces.
The same-day developments show both how rapid detection and containment can stop transmission and how limited the available countermeasures remain against Bundibugyo ebolavirus, the strain involved in both outbreaks.
Uganda completes the final countdown
The World Health Organization and Africa Centres for Disease Control and Prevention said Uganda had met the international benchmark for ending transmission linked to an Ebola outbreak. The 42-day period is twice the upper limit of Ebola’s incubation period and is used as an added safeguard against undetected chains of transmission.
Uganda’s last patient, an imported case from the Democratic Republic of the Congo, was discharged on July 16. Uganda announced that local transmission had been interrupted on July 28, but continued surveillance and completed the additional 42-day monitoring period before declaring the outbreak over on August 27.
Uganda recorded 20 confirmed cases, including 15 imported from the Democratic Republic of the Congo and five locally acquired among contacts and health workers linked to imported cases. Eighteen people recovered and two died. More than 800 contacts were identified and monitored.
According to WHO, the response relied on case detection and confirmation, contact tracing, isolation, clinical care, infection-prevention measures, community engagement, surveillance in health facilities and monitoring at points of entry. The declaration does not mean Uganda is permanently free of Ebola. Surveillance, testing capacity and cross-border preparedness are continuing.
Congo launches vaccination in Kisangani
On the same day, Congo officially launched an Ebola vaccination campaign in Kisangani, the capital of Tshopo province. Health workers, other frontline responders and people who had contact with Ebola patients were among the first groups prioritized.
The campaign is expected to cover 14 health zones in Tshopo, Bas-Uélé and Haut-Uélé provinces. The Associated Press reported that more than 50,000 doses had been received, while WHO had approved 70,000 doses for use in Congo.
About 50,000 doses are intended for frontline and health workers. Another 20,000 are intended for a clinical trial examining whether Ervebo can protect against Bundibugyo Ebola, according to AP’s reporting on WHO and African health officials.
Why Ervebo is being studied
The vaccine being used, Ervebo, is approved to protect against Zaire ebolavirus. It is not specifically approved for Bundibugyo ebolavirus, the strain identified in the current outbreaks.
WHO says there is no vaccine specifically approved for Bundibugyo Ebola and no specific treatment for the strain. Ervebo is therefore being used under a compassionate-use program while researchers collect data on whether it provides protection against this different virus.
Health authorities say the two viruses are related and that Ervebo could offer some protection, but its ability to prevent illness from Bundibugyo Ebola remains under study. The vaccination campaign should not be treated as proof that the vaccine is effective against this strain or that Congo has contained the outbreak.
Congo’s outbreak remains active and expanding
WHO’s weekly situation report, using data through August 23, recorded 5,584 confirmed cases and 2,680 confirmed deaths in Congo. The agency said the outbreak had expanded from 55 to 57 affected health zones across six provinces.
The Associated Press, citing newer Congolese government figures, reported 5,713 confirmed cases and 2,744 deaths as of August 25. The different totals reflect the separate reporting cutoff dates.
AP reported that the affected provinces include Ituri, North Kivu, South Kivu, Tshopo, Haut-Uélé and Bas-Uélé. WHO has described the outbreak as involving sustained transmission, high mortality and continued geographic expansion, with insecurity, displacement, humanitarian pressures and population movement complicating the response.
What it means for the region
Uganda’s milestone demonstrates the value of early case detection, contact tracing, isolation, clinical preparedness and community cooperation. But the outbreak’s cross-border origin and Congo’s continuing transmission mean neighboring countries remain at risk of imported cases.
WHO continues to advise against broad travel and trade restrictions related to the outbreak. It does not recommend suspending flights, closing borders or denying entry to travelers from affected countries. Instead, countries are being urged to maintain proportionate measures such as surveillance, rapid alert investigation, testing, infection prevention and cross-border coordination.
For travelers, businesses and communities, that means there is no general regional border shutdown under current guidance, although requirements and precautions in directly affected areas may change as health authorities receive new information.
Sources
- WHO Africa: Uganda ends Ebola outbreak following completion of 42-day countdown
- Associated Press: Health workers in Congo receive Ebola vaccine amid outbreak
Look for updates to this story
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.